Endocrine Disorders: Evaluation and Management

  • Author: Todd T. Brown, MD (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 11/14/16 (What's New)

Summary

  • Exenatide and liraglutide are subcutaneously administered analogues of the gut hormone GLP-1
  • Major adverse effect of exenatide and liraglutide is gastrointestinal upset
  • Liraglutide is contraindicated in patients with a personal or family history of medullary thyroid cancer or in patients with multiple endocrine neoplasia syndrome type 2

Action required

Keywords: Diabetes, Endocrine Disorders

©2018 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.